

Please amend claims 1-4, 8, 13-19 and 21-25 have been amended as follows:

- Sub C*
1. (Amended) A process for the manufacture of a solid dosage form which is rapidly dissolving in aqueous medium, wherein the solid dosage form comprising an active substance and other pharmaceutical ingredients suitable for a solid dosage and wherein the solid dosage form is a pharmaceutical or veterinary dosage form for oral administration, which process comprises
- (a) preparing a powder or granulate consisting of
    - (1) either the active substance or part thereof and the other ingredients of the solid dosage form, or
    - (2) the other ingredients of the solid dosage form;
  - (b) dispensing
    - (1) either an auxiliary solvent or
    - (2) a solution or dispersion of the active substance in an auxiliary solvent in cavities of a pre-formed container intended for storage of the solid dosage form or molds;
  - (c) compacting a suitable amount of the powder or granulate prepared according to (a)(1) or (a)(2) above;
  - (d) putting the compacted powder or granulate prepared according to (c) on the top of the solvent which according to (b)(1) or (b)(2) is in the molds or in the cavities of the pre-formed container intended for storage of the solid dosage form;
  - (e) removing the auxiliary solvent by applying a drying system to the molds or the cavities of the pre-formed container intended for storage of the solid dosage form; and
  - (f) removing the dried solid dosage form from the moulds into a suitable storage container or sealing the cavities of the pre-formed container intended for storage of the solid dosage form, respectively.

2. ( Amended) A process according to claim 1 for the manufacture of a solid, rapidly dissolving pharmaceutical or veterinary dosage form for oral administration, which process comprises

(a) preparing a powder or granulate consisting of

- 132  
cont*
- (1) either the intended dose of the active substance or part thereof and the other ingredients of the solid dosage form, or
  - (2) the other ingredients of the solid dosage form;

(a') transferring the powder or granulate to a combined compacting/dosing system; and

(a'') placing the molds or the pre-formed container intended for storage of the solid pharmaceutical or veterinary dosage form within the operating range of the combined compacting/dosing system;

(b) dispensing,

- (1) either an auxiliary solvent or
- (2) a solution or dispersion of the active substance in an auxiliary solvent, in the molds or in the cavities of the pre-formed container intended for storage of the solid pharmaceutical or veterinary dosage form;

(c) compacting - within the combined compacting/dosing system - a suitable amount of the powder or granulate prepared according to (a)(1) or (a)(2) above;

(d) putting the compacted powder or granulate on the top of the liquid which according to (b)(1) or (b)(2) is in the molds or in the cavities of the pre-formed container intended for storage of the solid pharmaceutical or veterinary dosage form;

(e) removing the auxiliary solvent by applying a drying system comprising one or more techniques selected from the group consisting of forced warm gas, microwave radiation and

reduced pressure, to the units in the moulds or in the cavities of the pre-formed container intended for storage of the solid dosage form; and

(f) removing the dried units from the moulds into a suitable storage container or sealing the cavities of the pre-formed container intended for storage of the solid pharmaceutical or veterinary dosage form, respectively.

*B2  
Cont*  
3. (Amended) A process according to claim 1 for the manufacture of a solid, rapidly dissolving pharmaceutical dosage form for oral administration, which process comprises

(a) preparing a powder or granulate consisting of the active substance and all other ingredients of the solid dosage form;

(a') transferring the powder or granulate to a combined compacting/dosing system;

(a'') placing a pre-formed container intended for storage of the solid pharmaceutical dosage form within the operating range of the combined compacting/dosing system;

(b) dispensing an auxiliary solvent in the cavities of the pre-formed container intended for storage of the solid pharmaceutical dosage form;

(c) compacting - within the combined compacting/dosing system - an amount of the powder or granulate prepared according to (a) above, which amount of powder or granulate contains the intended dose of the active substance;

(d) putting the compacted powder or granulate on the top of the liquid which according to (b) is in the cavities of the pre-formed container intended for storage of the solid pharmaceutical dosage form;

(e) removing the auxiliary solvent by applying a drying system comprising at least two different techniques selected from the group consisting of forced warm gas, microwave radiation and reduced pressure; and

(f) sealing the cavities of the pre-formed container intended for storage of the solid pharmaceutical dosage form.

B2  
Contd

4. (Twice Amended) A process according to claim 1, where in step (b) the auxiliary solvent is selected from the group consisting of water, ethanol, acetone, isopropanol and any mixtures thereof.

B3

8. (Twice Amended) A process according to claim 1, where in step (e) the auxiliary solvent is removed by applying simultaneously or sequentially at least two different techniques selected from the group consisting of forced warm gas, microwave radiation and reduced pressure.

B4

13. (Amended) A solid dosage form according to claim 12, comprising

(1) a pharmaceutically or veterinary active substance,  
(2) a filler selected from the group consisting of mannitol, lactose, calcium phosphates, dibasic calcium phosphates, microcrystalline cellulose, cyclodextrine, starch, laevulose, maltitol, polydextrose, sucrose, glucose, inulin, sorbitol or xylitol, and  
(3) a disintegration agent selected from the group consisting of croscarmellose Na; agents based on sodium carboxymethyl cellulose and starch, sodium glycolates of starches, poly-N-vinyl-2-pyrrolidones, starches, polymethylmethacrylates, polysaccharides or synthetic resins.

14. (Amended) A solid dosage form according to claim 12, comprising

(1) a pharmaceutically or veterinary active substance,  
(2) mannitol, lactose, starch and microcrystalline cellulose, and  
(3) a disintegration agent selected from the group consisting of croscarmellose Na, agents based on sodium carboxymethyl cellulose and starch, and poly-N-vinyl-2-pyrrolidones.

15. (Amended) A solid dosage form according to claim 12, consisting essentially of a homogeneous mixture of

- (1) at least one pharmaceutically or veterinary active substance,
- (2) at least one filler,
- (3) at least one disintegration agent, and
- (4) optionally pharmaceutically or veterinarilly acceptable excipients,

which dosage form disintegrates when taken into the mouth within 30 seconds, and which dosage form has a density of 400-900 mg/ml.

134  
cont'd

16. (Amended) A solid dosage form according to claim 15, consisting essentially of a homogeneous mixture of

- (1) at least one pharmaceutically active substance,
- (2) at least one filler selected from the group consisting of mannitol, lactose, calcium phosphates, dibasic calcium phosphates, microcrystalline cellulose, cyclodextrine, starch, laevulose, maltitol, polydextrose, sucrose, glucose, inulin, sorbitol or xylitol,
- (3) a disintegration agent selected from the group consisting of croscarmellose Na; agents based on sodium carboxymethyl cellulose and starch, sodium glycolates of starches, poly-N-vinyl-2-pyrrolidones, starches, polymethylmethacrylates, polysaccharides or synthetic resins, and
- (4) optionally pharmaceutically acceptable excipients.

17. (Amended) A solid dosage form according to claim 15, consisting essentially of a homogeneous mixture of

- (1) a pharmaceutically or veterinary active substance,
- (2) mannitol,
- (3) a disintegration agent selected from the group consisting of croscarmellose Na, agents based on sodium carboxymethyl cellulose and starch, and poly-N-vinyl-2-pyrrolidones; and
- (4) optionally pharmaceutically excipients.

18. (Twice Amended) A solid dosage form according to claim 12, wherein the active substance is selected from the group consisting of (a) diclofenac, ketoprofen, ibuprofen, aspirin,

paracetamol, melatonin and pharmaceutically acceptable salts thereof, and (b) pharmaceutically acceptable salts of calcium, magnesium and zinc.

*B4*  
*and*  
19. (Twice Amended) A solid dosage form according to claim 15, wherein the composition contains as one of the excipients (4) a lubricant.

*B5*  
21. (Twice Amended) A solid dosage form according to claim 15, wherein the composition contains as the excipients (4) comprising a lubricant, and one or more sweeteners.

22. (Twice Amended) A solid dosage form according to claim 12, wherein the filler (2) is present in an amount of at least 30 weight-%, and the disintegrating agent (3) is present in an amount of from 0.5 up to 15 weight-% of the total dosage form.

23. (Twice Amended) A solid dosage form according to claim 15, which dosage form is manufactured without applying any compression force to the mixture of the components (1), (2), (3) and optionally (4) during the last step of manufacture concerning the solid dosage form.

24. (Twice Amended) A solid dosage form according to claim 12, which dosage form is manufactured without applying any freeze-drying process.

25. (Twice Amended) A solid dosage form according to claim 15, which dosage form is manufactured by starting with the preparation of a homogeneous mixture of all the components (1), (2), (3) and optionally (4) of the dosage form.

Please add claim 27 as follows:

*B4*  
-- 27. A process for the manufacture of a solid dosage pharmaceutical composition which rapidly dissolves in an aqueous medium, comprising the steps of  
(a) preparing solid powder or granule forms of ingredients for the solid dosage composition, the ingredients including an active substance;